Baseline demographic data, clinical characteristics and laboratory findings in patients with RA and AS receiving 24 weeks of golimumab therapy†
| RA | EULAR responders (n=25) | Poor responders (n=8) |
| Mean age at study entry, years | 51.1±16.1 | 52.9±16.8 |
| Proportion of females, n (%) | 22 (88.0%) | 8 (100%) |
| Disease duration, years | 6.8±2.3 | 7.4±2.3 |
| RF positivity, n (%) | 18 (72%) | 7 (87.5%) |
| Anti-CCP positivity, n (%) | 16 (64%) | 6 (75.0%) |
| BMI (kg/m2) | 24.0±3.7 | 25.1±5.7 |
| CRP (mg/dL) | 2.02±2.31 | 2.68±1.80 |
| DAS28 | 6.27±0.84 | 6.51±0.80 |
| Concomitant DMARDs | ||
| Steroid dose (mg/day) | 3.9±2.1 | 6.7±2.6* |
| Methotrexate (mg/week) | 13.4±2.2 | 9.7±2.5* |
| Sulfasalazine, n (%) | 11 (44.0%) | 4 (50.0%) |
| Hydroxychloroquine, n (%) | 12 (48.0%) | 6 (75.0%) |
| AS | BASDAI50 responders (n=34) | Non-responder (n=9) |
|---|---|---|
| Mean age at study entry, years | 39.7±14.2 | 39.8±13.0 |
| Proportion of males, n (%) | 31 (91.2%) | 7 (77.8%) |
| Disease duration, years | 6.9±3.2 | 6.7±3.0 |
| HLA-B27 positivity, n (%) | 33 (97.1%) | 9 (100%) |
| BMI (kg/m2) | 24.1±4.62 | 23.1±2.11 |
| CRP (mg/dL) | 4.06±3.88 | 2.95±3.05 |
| BASDAI | 6.52±0.43 | 6.36±0.27 |
| ASDAS-CRP | 4.14±0.38 | 4.02±0.53 |
| Concomitant medications | ||
| NSAIDs, n (%) | 34 (100%) | 9 (100%) |
| Methotrexate, n (%) | 8 (23.5%) | 1 (11.1%) |
| Sulfasalazine, n (%) | 24 (70.6%) | 6 (66.7%) |
EULAR responders including good responders and moderate responders: good responders were defined as patients who had a decrease in DAS28 from baseline (ΔDAS28)>1.2 and a DAS28 ≤3.2 at evaluation time; and moderate responders had either ΔDAS28 >1.2 and a DAS28 >3.2 or ΔDAS28 of 0.6–1.2 and a DAS28 ≤5.1 at evaluation time; poor responders were those who had either ΔDAS28 <0.6 or a DAS28 >5.1 at evaluation time.
*p<0.005, versus EULAR responders.
†Data are presented as mean±SD or number (percentage).
Anti-CCP, anticyclic citrullinated peptide antibodies; AS, ankylosing spondylitis; ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score using C reactive protein; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BMI, body mass index; CRP, C reactive protein; DAS28, disease activity score for 28 joints; DMARDs, disease-modifying antirheumatic drugs; EULAR, European League Against Rheumatism; HLA-B27, human leucocyte antigen-B27; NSAIDs, non-steroid anti-inflammatory drugs; RA, rheumatoid arthritis; RF, rheumatoid factor.